Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Anti-CD38 monoclonal antibodies in multiple myeloma with gain/amplification of chromosome arm 1q: a review of the literature

3 May 2024

Abstract excerpt

INTRODUCTION: Gain/amplification of 1q (+1q) represents one of the most prevalent cytogenetic abnormalities (CAs) observed in multiple myeloma (MM). Historical studies predating the advent of anti-CD38 monoclonal antibodies (moAbs) implicated + 1q in poor prognoses, prompting its integration into novel staging systems. However, with the emergence of daratumumab and isatuximab, two pivotal anti-CD38 moAbs, the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Chronic Lymphocytic Leukemia Research
Share to Multiple Myeloma Research and Treatments
Share to Viral-associated cancers and disorders

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 38757726
DOI: 10.1080/14712598.2024.2357382

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 23 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Anti-CD38 monoclonal antibodies in multiple myeloma with gain/amplification of chromosome arm 1q: a review of the literaturePMID 38757726Read ↗

Clinical characteristics and treatment outcomes of newly diagnosed multiple myeloma with chromosome 1q abnormalitiesSemantic proximity Read ↗

Presence of 1q21 Gain and Amplification May be Associated With Poorer Outcomes in Daratumumab-treated Multiple Myeloma PatientsSemantic proximity Read ↗

Additional copies of 1q negatively impact the outcome of multiple myeloma patients and induce transcriptomic deregulation in malignant plasma cellsSemantic proximity Read ↗

International Myeloma Society/International Myeloma Working Group Consensus Recommendations on the Definition of High-Risk Multiple MyelomaSemantic proximity Read ↗

Targeting CD38 with Daratumumab Monotherapy in Multiple MyelomaSemantic proximity Read ↗

Pattern of Use and Efficacy of Daratumumab-based Therapy in Patients With Multiple Myeloma in a Real-world Setting: a Single Institution ExperienceSemantic proximity Read ↗

Clinical implications of cytogenetic and molecular aberrations in multiple myelomaSemantic proximity Read ↗

Gain/Amplification of Chromosome Arm 1q21 in Multiple MyelomaSemantic proximity Read ↗

Potential role of daratumumab in the treatment of multiple myelomaSemantic proximity Read ↗

Role of 1q21 in Multiple Myeloma: From Pathogenesis to Possible Therapeutic TargetsSemantic proximity Read ↗

Cytogenetic abnormalities in multiple myeloma: association with disease characteristics and treatment responseSemantic proximity Read ↗

Risk Stratification and Targets in Multiple Myeloma: From Genomics to the BedsideSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.